Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,601–2,700 of 15,747
Fusco, M. D., Marczell, K., Deger, K. A., Moran, M. M., Wiemken, T. L., Cane, A. D., de Boisvilliers, S., Yang, J., Vaghela, S., & Roïz, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2071427 · Cited by 46
Parthymou, A., Habeos, E. E., Habeos, G. I., Deligakis, A., Livieratos, E., Marangos, M. N., & Chartoumpekis, D. V. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057084 · Cited by 57
Ye, X., Ma, T., Blais, J. E., Yan, V. K. C., Kang, W. C. M., Chui, C. S. L., Lai, F. T. T., Li, X., Wan, E. Y. F., Wong, C. K. H., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac068 · Cited by 48
Vitamins, supplements and COVID-19: a review of currently available evidence
Speakman, L., Michienzi, S. M., & Badowski, M. E. (2021) · Drugs in Context · doi:10.7573/dic.2021-6-2 · Cited by 51
Buchy, P., Buisson, Y., Cintra, O. A. L., Dwyer, D. E., Nissen, M. D., de Lejarazu, R. O., & Petersen, E. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.045 · Cited by 51
Syenina, A., Gan, E. S., Toh, J. Z. N., de Alwis, R., Lin, L. Z., Tham, C. Y. L., Yee, J. X., Leong, Y. S., Sam, H., Cheong, C., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001643 · Cited by 49
“However, while these vaccines are remarkably efficacious against COVID-19, they are reactogenic [3,4].”
BackgroundPerceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey
Moujaess, E., Zeid, N. B., Samaha, R., Sawan, J., Kourié, H. R., Labaki, C., Chebel, R., Chahine, G. Y., Karak, F. E., Nasr, F. L., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0265 · Cited by 50
Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 42
Anastassopoulou, C. G., Antoni, D., Manoussopoulos, Y. N., Stefanou, P., Argyropoulou, S., Vrioni, G., & Tsakris, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266958 · Cited by 46
Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 54
“The remarkable success of mRNA vaccines, such as BNT162b2 and mRNA-1273, is largely attributed to LNPs, which protect mRNA from enzymatic degradation while facilitating efficient cellular uptake and cytoplasmic release, thereby ensuring robust antigen expression [117,267].”
Streinu‐Cercel, A., Săndulescu, O., Preoțescu, L., Kim, J. Y., Ys, K., Cheon, S., Jang, Y. R., Lee, S. J., Kim, S. H., Chang, I., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac053 · Cited by 49
Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials
Tang, J., Li, M., Zhao, C., Shen, D., Liu, L., Zhang, X., & Wei, L. (2022) · Viruses · doi:10.3390/v14020239 · Cited by 52
Hamm, S. R., Møller, D. L., Pérez‐Alós, L., Hansen, C. B., Pries‐Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., Fogh, K., Madsen, J. R., Armenteros, J. J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832501 · Cited by 46
Gil‐Vila, A., Ravichandran, N., Selva-O’Callaghan, A., Sen, P., Nune, A., Gaur, P. S., Gonzalez, R. A., Lilleker, J. B., Joshi, M. M., Agarwal, V., et al. (2022) · Muscle & Nerve · doi:10.1002/mus.27681 · Cited by 40
“5) 0 (0) 0 (0) 1 (2) 1 (1) 0 (0) Hospitalization 7 (0.”
InfluentialScope and challenges of nanoparticle-based mRNA delivery in cancer treatment
Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 47
Comparison of the 2021 COVID-19 roadmap projections against public health data in England
Keeling, M. J., Dyson, L., Tildesley, M. J., Hill, E. M., & Moore, S. (2022) · Nature Communications · doi:10.1038/s41467-022-31991-0 · Cited by 44
Michos, A. G., Tatsi, E., Filippatos, F., Dellis, C., Koukou, D., Efthymiou, V., Kastrinelli, E., Mantzou, A., & Syriopoulou, V. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.067 · Cited by 44
“Given the current global vaccine shortage, some researchers have proposed the delay of the administration of the 2 vaccine dose to ensure partial immunity to more individuals [8].”
Bathula, N. V., Friesen, J. J., Casmil, I. C., Wayne, C. J., Liao, S., Soriano, S. K. V., Ho, C.-H., Strumpel, A., & Blakney, A. K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.078 · Cited by 48
Landscape and progress of global COVID-19 vaccine development
Huang, H., Wang, S., Tang, Y., Sheng, W., Zuo, C., Wu, D., Fang, H., Du, Q., & Li, N. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1945901 · Cited by 46
Parry, H., Bruton, R. K., Tut, G., Ali, M., Stephens, C., Greenwood, D., Faustini, S. E., Hughes, S. A., Huissoon, A. P., Meade, R., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00169-0 · Cited by 45
Ahmed, S., Khan, S., Imran, I., Mughairbi, F. A., Sheikh, F. S., Hussain, J., Khan, A., & Al‐Harrasi, A. (2021) · Vaccines · doi:10.3390/vaccines9080836 · Cited by 45
“Some of these questions are yet to be answered and data to answer such questions are still lacking [23,28,86].”
BackgroundResultDomenico, L. D., Sabbatini, C. E., Boëlle, P., Poletto, C., Crépey, P., Paireau, J., Cauchemez, S., Beck, F., Noël, H., Lévy-Bruhl, D., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00057-5 · Cited by 51
Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection
Lewis, N., Chambers, L. C., Chu, H. T., Fortnam, T., Vito, R. D., Gargano, L. M., Chan, P. A., McDonald, J., & Hogan, J. W. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.23917 · Cited by 43
Alaje, A. I., & Olayiwola, M. O. (2023) · Healthcare Analytics · doi:10.1016/j.health.2023.100230 · Cited by 43
Acute Pancreatitis: A Possible Side Effect of COVID-19 Vaccine
Parkash, O., Sharko, A., Farooqi, A., Ying, G. W., & Sura, P. K. (2021) · Cureus · doi:10.7759/cureus.14741 · Cited by 44
Speich, B., Chammartin, F., Abela, I. A., Amico, P., Stoeckle, M. P., Eichenberger, A. L., Hasse, B. K., Braun, D. L., Schuurmans, M. M., Müller, T. F., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac169 · Cited by 46
“Both vaccines were tested in largescale placebocontrolled approval studies including tens of thousands of individuals [5, 6].”
Bonadonna, P., Brockow, K., Niedoszytko, M., Elberink, H. O., Akin, C., Nedoszytko, B., Butterfield, J. H., Álvarez‐Twöse, I., Sotlar, K., Schwaab, J., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.041 · Cited by 47
COVID-19 vaccine-related interstitial lung disease: a case study
Park, J. Y., Kim, J., Lee, I. J., Kim, H. I., Park, S., Hwang, Y. I., Jang, S. H., & Jung, K. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217609 · Cited by 41
Bolsoni, J., Liu, D. X., Mohabatpour, F., Ebner, R., Sadhnani, G., Tafech, B., Leung, J., Shanta, S. R., An, K., Morin, T., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c08644 · Cited by 45
“25,26 These success stories have sparked an unparalleled interest in LNPs for gene delivery.”
Covid-19 vaccination: evidence of waning immunity is overstated
Scott, J. A., Richterman, A. G., & Çevik, M. (2021) · BMJ · doi:10.1136/bmj.n2320 · Cited by 39
Mücke, V. T., Knop, V., Mücke, M. M., Ochsendorf, F. R., & Zeuzem, S. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06655-x · Cited by 42
“So far, serious adverse events reported with mRNA-vaccines, especially BNT162b2 are rare and efficacy rates are high [18].”
BackgroundAchtnichts, L., Jakopp, B., Oberle, M., Nedeltchev, K., Fux, C. A., Sellner, J., & Findling, O. (2021) · Vaccines · doi:10.3390/vaccines9121470 · Cited by 45
“, 28010 Madrid, Spain) vaccines proved efficacious in phase 3 trials and were the only licensed vaccines against SARS-CoV-2 in Switzerland until October 2021 [6,7].”
BackgroundBenefit of COVID-19 Vaccination Accounting for Potential Risk Compensation
Ioannidis, J. P. A. (2021) · npj Vaccines · doi:10.1038/s41541-021-00362-z · Cited by 47
Nanoparticle approaches against SARS-CoV-2 infection
Duan, Y., Wang, S., Zhang, Q., Gao, W., & Zhang, L. (2021) · Current Opinion in Solid State and Materials Science · doi:10.1016/j.cossms.2021.100964 · Cited by 43
Cohen, D., Krauthammer, S. H., Cohen, Y. C., Perry, C., Avivi, I. M., Herishanu, Y., & Even‐Sapir, E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05389-x · Cited by 45
“investigated the safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine in healthy adults or those with chronic stable medical conditions, excluding patients treated with immunosuppressive therapies or diagnosed with immunocompromising conditions [1].”
BackgroundThe Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Wei, J., & Hui, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s341694 · Cited by 47
“BNT162b2 is a modRNA vaccine that expresses P2 mutant, prefusion spike glycoprotein (P2 S) (version 9).(42,43)”
BackgroundCerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia
Siegler, J. E., Klein, P., Yaghi, S. R., Vigilante, N. F., Abdalkader, M. K., Coutinho, J. M., Khalek, F. A., & Nguyen, T. N. (2021) · Stroke · doi:10.1161/strokeaha.121.035613 · Cited by 44
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 41
Lenart, K., Hellgren, F., Ols, S., Yan, X., Cagigi, A., Cerveira, R. A., Winge, I. P., Hanczak, J., Mueller, S. O., Jasny, E., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.001 · Cited by 43
Washrawirul, C., Triwatcharikorn, J., Phannajit, J., Ullman, M., Susantitaphong, P., & Rerknimitr, P. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18294 · Cited by 43
Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
Nguyen, T. T., Quach, T. H. T., Tran, T. M., Phuoc, H. N., Nguyen, H. T., Vo, T. K., & Vo, G. V. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112650 · Cited by 41
Delivery of synthetic mRNAs for tissue regeneration
Steinle, H., Weber, M., Stoppelkamp, S., Große‐Berkenbusch, K., Golombek, S., Weber, M., Çanak-Ipek, T., Trenz, S.-M., Schlensak, C., & Avci‐Adali, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114007 · Cited by 43
Ryckman, T. S., Chin, E. T., Prince, L., Leidner, D., Long, E., Studdert, D. M., Salomon, J. A., Alarid‐Escudero, F., Andrews, J. R., & Goldhaber‐Fiebert, J. D. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00162-6 · Cited by 53
Love, J., Keegan, L. T., Angulo, F. J., McLaughlin, J. M., Shea, K. M., Swerdlow, D. L., Samore, M. H., & Toth, D. J. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-97612-w · Cited by 40
Sources of bias in observational studies of covid‐19 vaccine effectiveness
Fung, K., Jones, M., & Doshi, P. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13839 · Cited by 49
Nanomedicines Targeting Respiratory Injuries for Pulmonary Disease Management
Liu, D., Long, M., Gao, L., Chen, Y., Fang, L., Shi, Y., & Gu, N. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202112258 · Cited by 52
Marra, A. R., Sampaio, V. D. S., Ozahata, M. C., Lopes, R., Brito, A. F., Bragatte, M. A. D. S., Kalil, J. E., Miraglia, J. L., Malheiro, D. T., Guozhang, Y., et al. (2023) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.95 · Cited by 50
Jahn, B., Sroczynski, G., Bicher, M., Rippinger, C., Mühlberger, N., Santamaria, J., Urach, C., Schomaker, M., Stojkov, I., Schmid, D., et al. (2021) · Vaccines · doi:10.3390/vaccines9050434 · Cited by 42
“Currently approved vaccines showed greater effectiveness in initial trials [38,39].”
BackgroundMwimanzi, F. M., Lapointe, H. R., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac199 · Cited by 45
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Hsieh, C., Leist, S. R., Miller, E. H., Zhou, L., Powers, J. M., Tse, A. L., Wang, A., West, A., Zweigart, M. R., Schisler, J. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45404-x · Cited by 46
Acceptance of COVID-19 Vaccine Among Refugees in the United States
Zhang, M., Gurung, A., Anglewicz, P. A., Subedi, P., Payton, C., Ali, A., Ibrahim, A., Haider, M. Z., Hamidi, N., Atem, J., et al. (2021) · Public Health Reports · doi:10.1177/00333549211045838 · Cited by 42
Intervention Tournaments: An Overview of Concept, Design, and Implementation
Hameiri, B., & Moore‐Berg, S. L. (2022) · Perspectives on Psychological Science · doi:10.1177/17456916211058090 · Cited by 49
Liang, X., Xu, Q., Jia, Z.-J., Wu, M., Liu, Y., Lin, L., Liu, L., & Yang, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876037 · Cited by 45
Ghazy, R. M., ElHafeez, S. A., Shaaban, R., Elbarazi, I., Kheirallah, K. A., Abdou, M. S. M., & Ramadan, A. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211018568 · Cited by 41
Lv, J., Wu, H., Xu, J., & Liu, J. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00977-x · Cited by 43
“Several vaccines with proven effectiveness are being deployed globally, including Pfizer-BioNTech’s mRNA COVID-19 vaccine (BNT) [5], Oxford–AstraZeneca’s adenovirus vectored vaccine (ChAd) [6], China’s Sinovac [7], and Sinopharm vaccines [8].”
MethodStrategies for induction of HIV‐1 envelope‐reactive broadly neutralizing antibodies
Williams, W. B., Wiehe, K. J., Saunders, K. O., & Haynes, B. F. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25831 · Cited by 46
“The Moderna [60] and PfizerBioNTech [61] SARS-CoV-2 vaccines used a modified messenger ribonucleic acid (mRNA) encoding the SARS-CoV-2 spike protein encapsulated in a lipid nanoparticle as a delivery platform. mRNA-based vaccines have previously shown remarkable success in inducing protective immunity against ZIKA vir…”
MethodEngineered multi-domain lipid nanoparticles for targeted delivery
Liu, Z., Chen, J., Xu, M., Ho, S., Wei, Y., Ho, H., & Yong, K. (2025) · Chemical Society Reviews · doi:10.1039/d4cs00891j · Cited by 70
Zani, A., Caccuri, F., Messali, S., Bonfanti, C., & Caruso, A. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1940305 · Cited by 43
Kumar, G., & Ardekani, A. M. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01716 · Cited by 56
Riccò, M., Ferraro, P., Peruzzi, S., Balzarini, F., & Ranzieri, S. (2021) · Vaccines · doi:10.3390/vaccines9080889 · Cited by 43
Agbarya, A., Sarel, I., Ziv‐Baran, T., Agranat, S., Schwartz, O., Shai, A., Nordheimer, S., Fenig, S., Shechtman, Y., Kozlener, E., et al. (2021) · Cancers · doi:10.3390/cancers13164191 · Cited by 43
“Patients undergoing treatment with immunosuppressive therapy, including anti-cancer therapy, were excluded from the clinical trials [7].”
BackgroundNanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 49
Lytras, T., Kontopidou, F. V., Lambrou, A., & Tsiodras, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27934 · Cited by 40
Jiang, F., Liu, Y., Xue, Y., Cheng, P., Wang, J., Lian, J., & Gong, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109728 · Cited by 45
“Currently, 199 vaccines are in preclinical development, 175 are in clinical trials, and more than ten COVID-19 vaccines have been approved for emergency use to prevent COVID-19, including BNT162b2 [1], mRNA-1273 [2], AZD1222 [3], Ad26.”
Ollila, T. A., Masel, R. H., Reagan, J. L., Lu, S., Rogers, R., Paiva, K. J., Taher, R., Burguera‐Couce, E., Zayac, A. S., Yakirevich, I., et al. (2022) · Cancer · doi:10.1002/cncr.34354 · Cited by 41
Risk factor targeting for vaccine prioritization during the COVID-19 pandemic
Chapman, L. A. C., Shukla, P. D., Rodríguez-Barraquer, I., Shete, P. B., León, T. M., Bibbins-Domingo, K. B., Rutherford, G. W., Schechter, R., & Lo, N. C. (2022) · Scientific Reports · doi:10.1038/s41598-022-06971-5 · Cited by 50
Acute macular neuroretinopathy following Pfizer-BioNTech COVID-19 vaccination
Valenzuela, D. A., Groth, S. L., Taubenslag, K. J., et al. (2021) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2021.101200 · Cited by 41
Akahata, W., Sekida, T., Nogimori, T., Ode, H., Tamura, T., Kono, K., Kazami, Y., Washizaki, A., Masuta, Y., Suzuki, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101134 · Cited by 41
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Straus, W., Urdaneta, V., Esposito, D. B., Mansi, J. A., Sanz Rodriguez, C., Burton, P., & Vega, J. M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac446 · Cited by 41
“These vaccines were evaluated in numerous clinical studies, including phase 3 studies that randomized approximately 15 000 individuals aged 18 years and older and 22 000 individuals aged 16 years and older to receive mRNA-1273 or BNT162b2, respectively, wherein the vaccines showed no serious safety concerns and were m…”
BackgroundReimann, P., Ulmer, H., Mutschlechner, B., Benda, M. A., Severgnini, L., Volgger, A., Lang, T., Atzl, M., Huynh, M., Gasser, K., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17982 · Cited by 42
Review: Vaccine Myth-Buster – Cleaning Up With Prejudices and Dangerous Misinformation
Löffler, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663280 · Cited by 47
Hensley, K. S., Jongkees, M. J., Geers, D., GeurtsvanKessel, C. H., Mueller, Y. M., Dalm, V. A. S. H., Papageorgiou, G., Steggink, H., Górska, A., Bogers, S., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003979 · Cited by 42
“In contrast to the phase III trials, we observed a lower response in male participants [1,2].”
ResultA safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination
Xu, S., Huang, R., Sy, L. S., Hong, V. X., Glenn, S. C., Ryan, D. S., Morrissette, K. L., Vazquez‐Benitez, G., Glanz, J. M., Klein, N. P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.036 · Cited by 48
Estimating the impact of interventions against COVID-19: From lockdown to vaccination
Thompson, J., & Wattam, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261330 · Cited by 46
Current Status of HIV-1 Vaccines
Hargrave, A., Mustafa, A. S., Hanif, A., Tunio, J. H., & Hanif, S. N. M. (2021) · Vaccines · doi:10.3390/vaccines9091026 · Cited by 43
“mRNA vaccines have been developed for Zika, influenza [32], and 2 vaccines for COVID-19 virus, BNT162b2 (Pfizer-BioNTech, New York, NY, USA) [33] and mRNA-1273 (Moderna, Cambridge, MA, USA) [34], and this is in part due to the lack of infectious risk, ease of manufacturing, and flexibility of immunogens associated wit…”
BackgroundTherapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 46
Basso, P., Negro, C., Cegolon, L., & Filon, F. L. (2022) · Viruses · doi:10.3390/v14020336 · Cited by 52
“The vaccination schedule for HCWs entails two-doses of BNT162b2 (30 μg per dose, given 21 days apart), a lipid nanoparticle-formulated, nucleoside-modified RNA (modRNA) encoding the SARS-CoV-2 full-length spike protein, that was found to be safe and 95% effective against COVID-19 [7].”
BackgroundChivu‐Economescu, M., Bleoţu, C., Grancea, C., Chiriac, D., Botezatu, A., Iancu, I. V., Pitica, I. M., Necula, L. G., Neagu, A. I., Matei, L., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17186 · Cited by 43
Watanabe, M., Balena, A., Masi, D., Tozzi, R., Risi, R., Caputi, A., Rossetti, R., Spoltore, M. E., Biagi, F., Anastasi, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10010079 · Cited by 45
“However, it should be highlighted that the immunogenicity of the mRNA COVID-19 vaccines is exceptionally high, as confirmed by the net reduction of infection and hospitalization following inoculation [32,33], and a lower adaptive response may be sufficiently effective, at least in the short term.”
BackgroundSARS-CoV-2 mRNA vaccination elicits robust antibody responses in children
Bartsch, Y. C., Denis, K. S., Kapłonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9237 · Cited by 60
Henriquez, S., Zerbit, J., Bruel, T., Ouedrani, A., Planas, D., Deschamps, P., Staropoli, I., Hadjadj, J., Varet, B. R., Suarez, F., et al. (2021) · Blood · doi:10.1182/blood.2021013714 · Cited by 48
Towards design of drugs and delivery systems with the Martini coarse-grained model
Kjølbye, L. R., Pereira, G. P., Bartocci, A., Pannuzzo, M., Albani, S., Marchetto, A., Jiménez‐García, B., Martin, J., Rossetti, G., Cecchini, M., et al. (2022) · QRB Discovery · doi:10.1017/qrd.2022.16 · Cited by 46
“Lisbeth R. cationic polymers for delivery of NAs, which proved invaluable at the outbreak of the COVID-19 pandemic (Polack et al ., 2020; Baden et al ., 2021).”
BackgroundEngineered mRNA Delivery Systems for Biomedical Applications
Wang, J., Zhu, H., Gan, J., Liang, G., Li, L., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202308029 · Cited by 50
RNA and Protein Delivery by Cell‐Secreted and Bioengineered Extracellular Vesicles
Wang, B. Z., Luo, L. J., & Vunjak‐Novakovic, G. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101557 · Cited by 50
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 68
Neuropathic symptoms with SARS-CoV-2 vaccinationPreprint
Safavi, F., Gustafson, L., Walitt, B. T., Lehky, T., Dehbashi, S., Wiebold, A., Mina, Y., Shin, S. C., Pan, B., Polydefkis, M. J., et al. (2022) · medRxiv · doi:10.1101/2022.05.16.22274439 · Cited by 49
“The vaccines received included one manufactured by AstraZeneca (ChAdOx1 nCoV19),(13) one by Janssen (JNJ-78436735), nine by Moderna (mRNA-1273)(14) and 12 by Pfizer-BioNTech (BNT162b2).(15) Fourteen participants (65%) developed neurological symptoms following the first dose.”
Fine needle aspiration in COVID-19 vaccine-associated lymphadenopathy
Hagen, C., Nowack, M., Messerli, M., Saro, F., Mangold, F., & Bode, P. K. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.20557 · Cited by 39
Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers
Dietmair, B., Humphries, J., Mercer, T. R., Thurecht, K. J., Howard, C. B., & Cheetham, S. W. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102520 · Cited by 51
Saciuk, Y., Kertes, J., Mandel, M., Hemo, B., Shamir-Stein, N., & Zohar, A. E. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106947 · Cited by 43
“With an average of two months follow-up from day seven after the second vaccination, only eight new cases of 18,198 infection naïve participants developed symptoms in the intervention group, compared with 162 new cases in a similar population group that received the placebo.(2)”
BackgroundResultAmanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
Schulze, C., Welker, A., Kühn, A., Schwertz, R., Otto, B., Moraldo, L., Dentz, U., Arends, A., Welk, E., Wendorff, J.-J., et al. (2021) · Vaccines · doi:10.3390/vaccines9080887 · Cited by 52
Modeling waning and boosting of COVID-19 in Canada with vaccination
Childs, L. M., Dick, D. W., Feng, Z., Heffernan, J. M., Li, J., & Röst, G. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100583 · Cited by 44
“dose efficacies of available vaccines (Polack et al., 2020), as well as the”
BackgroundDong, L., Deng, X., Li, Y., Zhu, X., Shu, M., Chen, J., Luo, H., An, K., Cheng, M., Zhang, P., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c04331 · Cited by 43
Ntouros, P. A., Vlachogiannis, N. I., Pappa, M. B., Nezos, A., Mavragani, C. P., Tektonidou, M. G., Souliotis, V. L., & Sfikakis, P. P. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108765 · Cited by 42
Cuapio, A., Boulouis, C., Filipovic, I., Wullimann, D., Kammann, T., Parrot, T., Chen, P., Akber, M., Gao, Y., Hammer, Q., et al. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00443-2 · Cited by 44
Hassan, A. O., Feldmann, F., Zhao, H.-Y., Curiel, D., Okumura, A., Tang-Huau, T.-L., Case, J., Meade-White, K., Callison, J. A., Lovaglio, J., et al. (2021) · bioRxiv · doi:10.1101/2021.01.26.428251 · Cited by 84
Humoral response to two doses of BNT162b2 vaccination in people with HIV
Heftdal, L. D., Knudsen, A. D., Hamm, S. R., Hansen, C. B., Møller, D. L., Pries‐Heje, M. M., Fogh, K., Hasselbalch, R. B., Jarlhelt, I., Pérez‐Alós, L., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13419 · Cited by 38
Should a third booster dose be scheduled after two doses of CoronaVac? A single‐center experience
Yiğit, M., Parlakay, A. Ö., Coşgun, Y., İnce, Y. E., Bulut, Y., & ŞENEL, E. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27318 · Cited by 41
“The efficiency of BNT162b2mRNA was found to be 95% in a Phase 3 study with more than 43 000 participants, and no significant difference was found between age groups in terms of effectiveness.(9) In the Phase 3 study of another messenger RNA (mRNA) vaccine—mRNA‐1273 (Moderna) —which included 30 000 patients, the effect…”
BackgroundChaudhary, J. K., Yadav, R., Chaudhary, P. K., Maurya, A., Kant, N., Rugaie, O. A., Haokip, H. R., Yadav, D., Roshan, R., Prasad, R., et al. (2021) · Cells · doi:10.3390/cells10112949 · Cited by 45
“Comirnaty (formerly BNT162b2) Two doses, 21 days apart, intramuscular injection Pfizer, BioNTech; Fosun Pharma Multinational/EMA 1/2 ( NCT04380701) 2 ( NCT04649021) 2/3 ( NCT04368728) Approved ~90% efficacy in phase 3 clinical trail [43,44]”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.